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LETTERS TO THE EDITORRegarding “Outcomes of covered versus bare-metal
balloon-expandable stents for aortoiliac occlusive
disease”
With interest we have read the paper by Humphries et al, who
have performed a retrospective cohort study comparing outcome
of bare-metal stents (BMSs) with balloon-expandable covered
(CBE) stents.1 They concluded that BMSs are superior to CBE
stents at 3 years in the treatment of aortoiliac occlusive disease.
This is in conﬂict with other studies, including the Covered Versus
Balloon Expandable Stent Trial (COBEST), which is the only pub-
lished randomized trial of CBE stents for aortoiliac occlusive dis-
ease to date, and another historical cohort study. Both showed
signiﬁcantly better results in terms of restenosis and reinterventions
in the use of CBE stents, especially in more complex lesions.2,3
There are a few points that might have biased the results of the
present study, both related to clinical decision making. First, the
choice of CBE stents or BMSs was decided on a case-by-case basis,
without describing why a certain stent was chosen. There were no
differences between groups in lesion length or TransAtlantic Inter-
Society Consensus (TASC) classiﬁcation, but that does not exclude
differences between groups. Factors such as occlusion vs stenosis
and the presence of mural thrombus or calciﬁcations are not
included in the TASC classiﬁcation. The more costly CBE stents
are regularly reserved for speciﬁc, often more complex indications
in which these CBE stents might have a beneﬁt above BMSs,
thereby justifying the use of these more expensive stents.
Second, and even more important, they have shown that the
primary patency was signiﬁcantly lower in the CBE stent group.
Loss of primary patency was deﬁned as any stent that underwent
reintervention to prevent thrombosis or any stent that thrombosed
primarily. The decision for reintervention was made, again and un-
fortunately, on a case-by-case basis. It seems reasonable to assume
that an indication for a reintervention on a focal edge stenosis to
preserve patency in an expensive CBE stent might have been
more attractive than reintervening in a patient with a diffuse in-
stent restenosis without clinical symptoms. This may have severely
affected the outcome of this study, and it was for that reason that
Diehm et al have suggested replacement of the term patency with
absence of binary restenosis and occlusion in endovascular studies, as
was done in the COBEST.3,4 This would have excluded the clinical
decision-making process as a bias and would have provided real ev-
idence on the performance of CBE stents vs BMSs.
In summary, the result of this study merely reﬂects the clinical
performance of these stents in this particular center, but we agree
with the authors that more randomized studies, such as the Dutch
DISCOVER trial, are indicated before the use of CBE stents is
considered standard care.5
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Our study concluded that the primary patency of bare-metal
stents (BMSs) is superior to that of covered balloon-expandable
(CBE) stents,1 although on the basis of the relatively small number
of patients evaluated, this may be an overstatement. Our work
describes the bias of vascular specialists to use BMSs rather than
CBE stents in treating aortoiliac occlusive disease and supports
the lack of sufﬁcient data to change this practice pattern. This
work is observational and has inherent biases, but vascular special-
ists are looking for guidance to support decision making. The
Covered Versus Balloon Expandable Stent Trial (COBEST),2
despite being a randomized controlled trial, does not answer the
question of when and for what lesions a CBE stent should be
chosen. COBEST has limitations, most notably the use of binary
restenosis as the primary end point, the vague criteria for deﬁning
restenosis, the absence of data on which imaging modalities were
used to diagnose the restenoses and how many of these restenoses
where conﬁrmed by angiography, and the lack of power for the
subgroup analyses that were performed.
When the design of the COBEST trial is considered, it is
important to remember that the trial was designed as a noninfer-
iority trial and that the only conclusion that can be drawn is that
CBE stents are no worse than BMSs for the outcome of binary
restenosis. Diehm et al3 have called for standardization of out-
comes and argued that restenosis be used as an outcome, rather
than patency. Restenosis allows comparison of the technical as-
pects of how stents perform head to head, but this is not neces-
sarily a meaningful outcome for patients. We do not need
another explanatory study to inform us of the safety and efﬁcacy
of covered stents. We need more pragmatic studies that look at
how these treatments perform in average patients and must face
the reality that decisions for reintervention are always made on
a case-by-case basis.
An additional limitation of COBEST is the lack of transpar-
ency in regard to conﬁrmation of stenosis. It has been well estab-
lished that in the carotid4 and mesenteric5 arteries, velocity criteria
to diagnose stenosis of stented arteries can be different from the
